On improving the safety of new direct acting oral anticoagulants
One of the main causes of death and disability in the world are the thrombotic complications. Using of anticoagulants is the effective method of preventing of these life-threatening conditions. However, the use of anticoagulants involves a significant risk of the bleeding. Safety of anticoagulants p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2018-02-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/43 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849252354440822784 |
|---|---|
| author | N. Yu. Velts M. A. Darmostukova A. S. Kazakov T. M. Bukatina O. E. Zhuravleva R. N. Alyautdin B. K. Romanov |
| author_facet | N. Yu. Velts M. A. Darmostukova A. S. Kazakov T. M. Bukatina O. E. Zhuravleva R. N. Alyautdin B. K. Romanov |
| author_sort | N. Yu. Velts |
| collection | DOAJ |
| description | One of the main causes of death and disability in the world are the thrombotic complications. Using of anticoagulants is the effective method of preventing of these life-threatening conditions. However, the use of anticoagulants involves a significant risk of the bleeding. Safety of anticoagulants predominately are determined by the availability of specific antidotes. Until now new oral directly acting anticoagulants do not have any specific antagonists. Idarutsizumab is the dagibatran-specific antagonist which increases its safety. |
| format | Article |
| id | doaj-art-d3bc133477e94d0cb08711e125546262 |
| institution | Kabale University |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| publishDate | 2018-02-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj-art-d3bc133477e94d0cb08711e1255462622025-08-20T03:56:40ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642018-02-0102283243On improving the safety of new direct acting oral anticoagulantsN. Yu. Velts0M. A. Darmostukova1A. S. Kazakov2T. M. Bukatina3O. E. Zhuravleva4R. N. Alyautdin5B. K. Romanov6Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsOne of the main causes of death and disability in the world are the thrombotic complications. Using of anticoagulants is the effective method of preventing of these life-threatening conditions. However, the use of anticoagulants involves a significant risk of the bleeding. Safety of anticoagulants predominately are determined by the availability of specific antidotes. Until now new oral directly acting anticoagulants do not have any specific antagonists. Idarutsizumab is the dagibatran-specific antagonist which increases its safety.https://www.risksafety.ru/jour/article/view/43риск развития кровотеченийдабигатранантидотидаруцизумабthe risk of bleedingdabigatranantidoteidarutsizumab |
| spellingShingle | N. Yu. Velts M. A. Darmostukova A. S. Kazakov T. M. Bukatina O. E. Zhuravleva R. N. Alyautdin B. K. Romanov On improving the safety of new direct acting oral anticoagulants Безопасность и риск фармакотерапии риск развития кровотечений дабигатран антидот идаруцизумаб the risk of bleeding dabigatran antidote idarutsizumab |
| title | On improving the safety of new direct acting oral anticoagulants |
| title_full | On improving the safety of new direct acting oral anticoagulants |
| title_fullStr | On improving the safety of new direct acting oral anticoagulants |
| title_full_unstemmed | On improving the safety of new direct acting oral anticoagulants |
| title_short | On improving the safety of new direct acting oral anticoagulants |
| title_sort | on improving the safety of new direct acting oral anticoagulants |
| topic | риск развития кровотечений дабигатран антидот идаруцизумаб the risk of bleeding dabigatran antidote idarutsizumab |
| url | https://www.risksafety.ru/jour/article/view/43 |
| work_keys_str_mv | AT nyuvelts onimprovingthesafetyofnewdirectactingoralanticoagulants AT madarmostukova onimprovingthesafetyofnewdirectactingoralanticoagulants AT askazakov onimprovingthesafetyofnewdirectactingoralanticoagulants AT tmbukatina onimprovingthesafetyofnewdirectactingoralanticoagulants AT oezhuravleva onimprovingthesafetyofnewdirectactingoralanticoagulants AT rnalyautdin onimprovingthesafetyofnewdirectactingoralanticoagulants AT bkromanov onimprovingthesafetyofnewdirectactingoralanticoagulants |